CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

75-796

ADMINISTRATIVE DOCUMENTS

ANDA **75-796** APPROVAL SUMMARY

PRODUCT: Levonorgestrel and Ethinyl Estradiol Tablets, USP

FIRM: Duramed Pharmaceuticals, Inc.

DOSAGE FORM: Tablet

STRENGTH: 0.10 mg/0.02 mg

cGMP STATEMENT/EIR UPDATE STATUS: Satisfactory
Acceptable EER on 05-MAR-2001

BIO STUDY: Approve, Per Bio Review Dated 04/19/00

VALIDATION: N/A, DS and DP are listed in the USP 24/NF 19

STABILITY: Three months accelerated (40°C/75%RH) and 9 months CRT (27°C±2°C) stability data for the unit dose blister container/closure system for Levonorgestrel and Ethinyl Estradiol Tablets lot C-0082 and Placebo Tablets lot C-0059, in 28 count (not over wrapped) and 10 count (overwrapped) were provided. The container/ closure system used for the stability study is equivalent to the system proposed for commercial use. All reported data are with in specifications as listed. Firm's stability data justifies a 24 month expiration date for the product.

Tests and specifications for the drug product on stability include: Appearance/description, container/closure, assay of label claim), dissolution (levonorgestrel NLT , in 60 minutes, ethinyl estradiol NLT in 60 minutes) and impurities/degradants (Total estradiol NMT , and Individual Unknown . Tests and specifications for Placebo tablets on stability include

LABELING: Satisfactory, labeling review dated 03/22/01

STERILIZATION VALIDATION: N/A

SIZE OF BIO BATCH: Levonorgestrel and Ethinyl Estradiol Batch # C-0082, tablets; Placebo Batch #S-0059, tablets.

SIZE OF STABILITY BATCHES: Stability batches are the same as the test/bio-batches.

PROPOSED PRODUCTION BATCHES: The proposed maximum production batch size for the Levonorgestrel and Ethinyl Estradiol tablets is lets and for the Placebo tablets is ablets. The manufacturing process for production batches remains the same as that for the ANDA batches.

CHEMIST: ***U.S. ATWAL, Ph.D.*** ***DATE:***

SUPERVISOR: ***D. Gill, Ph.D.*** ***DATE:***

ANDA 75-796

Duramed Pharmaceuticals, Inc.
Attention: John Rapoza
5040 Lester Road
Cincinnati, OH 45213

MAR 17 2000

Dear Sir:

We acknowledge the receipt of your abbreviated new drug application submitted pursuant to Section 505(j) of the Federal Food, Drug and Cosmetic Act.

Reference is also made to the telephone conversation dated March 7, 2000 and to your correspondence dated March 7, 2000.

NAME OF DRUG: Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.10 mg;0.02 mg

DATE OF APPLICATION: January 31, 2000

DATE (RECEIVED) ACCEPTABLE FOR FILING: February 1, 2000

We will correspond with you further after we have had the opportunity to review the application.

Please identify any communications concerning this application with the ANDA number shown above.

Should you have questions concerning this application, contact:

Ruby Yu
Project Manager
(301) 827- 5848

Sincerely yours,

Wm Peter Rickman
Acting Director
Division of Labeling and Program Support
Office of Generic Drugs
Center for Drug Evaluation and Research

AUG 12 2000

38. CHEMISTRY COMMENTS TO BE PROVIDED TO THE APPLICANT

ANDA: 75-796 APPLICANT: Duramed Pharmaceuticals, Inc.

DRUG PRODUCT: Levonorgestrel and Ethinyl Estradiol Tablets, USP 0.100 mg/0.02 mg

The deficiencies presented below represent MAJOR deficiencies.

A. Deficiencies:

1.

2.

3.

4.

5.

sults
e.
ment

6.

manufacturing record

Page(s) 1

Contain Trade Secret, Commercial/Confidential Information and are not releasable.

8/12/00

15. Please explain why you placed prep intermediates in stability.

16. Please revise your specifications for dissolution according to current USP specifications and provide revised stability protocol and finished product specification sheet.

B. In addition to responding to the deficiencies presented above, please note and acknowledge the following comments in your response:

1. A satisfactory CGMP compliance evaluation for the firms referenced in the ANDA is required for approval. We have requested an evaluation from the Division of Manufacturing and Product Quality.

2. Labeling portion of your application is under review. Deficiencies, if any, will be conveyed to you under separate cover.

3. Even though you have provided room temperature stability data for the prep intermediates in support of 12 months expiration dating, the expiration dating period for the tablets manufactured from the corresponding intermediates still will be counted from the date of manufacture of the powder intermediates.

Sincerely yours,

Rashmikant M. Patel, Ph.D.
Director
Division of Chemistry I
Office of Generic Drugs
Center for Drug Evaluation and Research